Halozyme Therapeutics (HALO) PT Raised to $58 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Halozyme Therapeutics (HALO) PT Raised to $73 at JMP Securities
November 1, 2024 3:42 AM EDTJMP Securities analyst Jason Butler raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $73.00 (from $72.00) while maintaining a Market Outperform rating.... More
Halozyme Therapeutics (HALO) Tops Q3 EPS by 31c, provides guidance
October 31, 2024 4:03 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of $1.27, $0.31 better than the analyst estimate of $0.96. Revenue for the quarter came in at $290 million versus the consensus estimate of $251.06 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $4.00-$4.20, versus the consensus of $3.96.... More
